The invention heart failure (particularly, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-factor-activated receptor (PPAR) gamma agonists - fluid retention, or salts, such as induced fluid retention It relates to compounds and methods for treating disorders associated with the overload. The invention also relates to compounds and methods for the treatment of high blood pressure. The invention also relates to compounds and methods for, the treatment of gastrointestinal disorders, including the treatment or reduction of pain associated with gastrointestinal disorders. The method, in general, necessary to mammalian gastrointestinal (GI) tube that is designed to be substantially active in inhibiting NHE- mediated yeoksusong of the sodium ion and hydrogen ion in the compound or in pharmaceutical compositions comprising these compounds of it comprises administering a pharmaceutically effective amount. More in particular, the method inhibits the NHE-3, -2 and / or -8 mediated yeoksusong of sodium ion and hydrogen ion in the GI tract of a mammal in need, and a layer of epithelial cells, more particularly in the epithelial layer of the GI tract a substantially it comprises administering a pharmaceutically effective amount of a pharmaceutical composition containing the compound or these compounds are designed to be impermeable for. The resulting compound is a substantially impermeable, this is not absorbed, so other internal organ thereof essentially non-systemic exposure that is limited (e.g., liver, heart, brain, etc.) - the bioavailability. The present invention also provides such a compound to a mammal, fluid - how to function as described the combination by administration with the absorbent polymer described above, and also provide the capability to isolate the fluid and / or the salts present in the GI tract It relates.본 발명은 심부전 (특히, 울혈성 심부전), 만성 신장질환, 말기 신장 질환, 간 질환, 및 퍼옥시좀 증식인자-활성화된 수용체 (PPA
